$1.54
6.21% yesterday
Nasdaq, Jan 06, 10:08 pm CET
ISIN
US67577C1053
Symbol
OCGN

Ocugen Inc Stock price

$1.54
+0.34 28.33% 1M
+0.57 58.76% 6M
+0.19 14.07% YTD
+0.64 71.19% 1Y
+0.24 18.46% 3Y
-1.07 41.00% 5Y
-206.66 99.26% 10Y
-703.46 99.78% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
+0.09 6.21%
ISIN
US67577C1053
Symbol
OCGN
Industry

Key metrics

Basic
Market capitalization
$452.9m
Enterprise Value
$448.7m
Net debt
positive
Cash
$32.6m
Shares outstanding
312.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
84.3 | 82.2
EV/Sales
83.6 | 81.4
EV/FCF
negative
P/B
128.3
Financial Health
Equity Ratio
35.9%
Return on Equity
-182.4%
ROCE
-160.5%
ROIC
-
Debt/Equity
8.0
Financials (TTM | estimate)
Revenue
$5.4m | $5.5m
EBITDA
$-56.4m | -
EBIT
$-59.8m | $-65.7m
Net Income
$-64.0m | $-71.4m
Free Cash Flow
$-53.5m
Growth (TTM | estimate)
Revenue
-48.1% | 35.8%
EBITDA
6.4% | -
EBIT
3.2% | -19.9%
Net Income
-3.9% | -32.0%
Free Cash Flow
-8.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,049.9% | -
EBIT
-1,112.9%
Net
-1,192.2% | -1,294.6%
Free Cash Flow
-996.8%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
19.2%
Employees
95
Rev per Employee
$40.0k
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Ocugen Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Ocugen Inc forecast:

Buy
91%
Hold
9%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5.37 5.37
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
13% 13%
517%
- Research and Development Expense 37 37
7% 7%
696%
-56 -56
6% 6%
-1,050%
- Depreciation and Amortization 3.38 3.38
119% 119%
63%
EBIT (Operating Income) EBIT -60 -60
3% 3%
-1,113%
Net Profit -64 -64
4% 4%
-1,192%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Positive
Seeking Alpha
about 21 hours ago
Ocugen remains a "Buy", driven by pivotal phase 2/3 GARDian3 trial progress for OCU410ST in Stargardt Disease. FDA and EMA regulatory alignment enables a single U.S. trial to support both BLA and MAA filings for OCU410ST, expediting potential approvals. Interim data from GARDian3 is expected by mid-2026, with possible BLA submission for OCU410ST in 2027 if results are positive.
Neutral
GlobeNewsWire
27 days ago
MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025. “For the second...
Neutral
GlobeNewsWire
about 2 months ago
MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen will present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference at Florida Atlantic University, E...
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today